Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncolytics Biotech ( (ONCY) ) has shared an update.
On October 10, 2025, Oncolytics Biotech Inc. submitted a corporate presentation to the Securities and Exchange Commission, highlighting the potential of pelareorep as a transformative immunotherapy platform for gastrointestinal tumors. The presentation detailed the mechanism of action, safety profile, and clinical experience of pelareorep, which has shown promising results in various cancer indications. This development positions Oncolytics Biotech as a key player in the oncology sector, potentially impacting stakeholders by offering a novel treatment option for patients with GI tumors.
The most recent analyst rating on (ONCY) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. operates in the biotechnology industry, focusing on developing innovative cancer therapies. The company’s primary product is pelareorep, an investigational double-stranded RNA immunotherapeutic agent aimed at treating gastrointestinal tumors, which are considered a significant unmet medical need in oncology.
Average Trading Volume: 1,046,902
Technical Sentiment Signal: Buy
Current Market Cap: $129.6M
Find detailed analytics on ONCY stock on TipRanks’ Stock Analysis page.